JP2020527540A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527540A5
JP2020527540A5 JP2019569444A JP2019569444A JP2020527540A5 JP 2020527540 A5 JP2020527540 A5 JP 2020527540A5 JP 2019569444 A JP2019569444 A JP 2019569444A JP 2019569444 A JP2019569444 A JP 2019569444A JP 2020527540 A5 JP2020527540 A5 JP 2020527540A5
Authority
JP
Japan
Prior art keywords
use according
dendritic cells
bid
dengue virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527540A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037616 external-priority patent/WO2018232166A1/en
Publication of JP2020527540A publication Critical patent/JP2020527540A/ja
Publication of JP2020527540A5 publication Critical patent/JP2020527540A5/ja
Pending legal-status Critical Current

Links

JP2019569444A 2017-06-15 2018-06-14 デングウイルスならびに樹状細胞を用いた癌治療のための組成物および方法 Pending JP2020527540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520345P 2017-06-15 2017-06-15
US62/520,345 2017-06-15
PCT/US2018/037616 WO2018232166A1 (en) 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells

Publications (2)

Publication Number Publication Date
JP2020527540A JP2020527540A (ja) 2020-09-10
JP2020527540A5 true JP2020527540A5 (enExample) 2021-07-26

Family

ID=64660234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569444A Pending JP2020527540A (ja) 2017-06-15 2018-06-14 デングウイルスならびに樹状細胞を用いた癌治療のための組成物および方法

Country Status (11)

Country Link
US (1) US20200121745A1 (enExample)
EP (1) EP3638303A4 (enExample)
JP (1) JP2020527540A (enExample)
KR (1) KR20200023375A (enExample)
CN (1) CN110996997A (enExample)
AU (1) AU2018285525A1 (enExample)
EA (1) EA201992863A1 (enExample)
IL (1) IL271442A (enExample)
MX (1) MX2019015194A (enExample)
SG (1) SG11201912163WA (enExample)
WO (1) WO2018232166A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004567A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN115666593B (zh) * 2020-05-21 2025-11-25 国立大学法人大阪大学 上皮癌治疗药
WO2022061811A1 (zh) * 2020-09-27 2022-03-31 深圳华大生命科学研究院 药物组合物及其制备方法和应用
CN116333969A (zh) * 2023-02-01 2023-06-27 宁波荣安生物药业有限公司 一种狂犬病毒用Vero细胞培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504322A (ja) * 1998-02-20 2002-02-12 ザ ロックフェラー ユニバーシティー 樹状細胞に対するアポトーシス細胞介在抗原提示
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
WO2017004567A1 (en) * 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
MX2018003757A (es) * 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus

Similar Documents

Publication Publication Date Title
JP2020527540A5 (enExample)
JP2017048208A5 (enExample)
JP2011251975A5 (enExample)
JP2015157821A5 (enExample)
CY1116874T1 (el) Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
MX2018012171A (es) Formulaciones novedosas que estabilizan e inhiben la precipitacion de composiciones inmunogenicas.
BR112014008551A2 (pt) conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento
JP2013505205A5 (enExample)
CY1111259T1 (el) Απο του στοματος εντερικη στερεα μορφη δοσολογιας ενος δισφωσφονικου που περιεχει παραγοντα χηλικης συμπλεξης
JP2016512248A5 (enExample)
JP2012136541A5 (enExample)
TW200630093A (en) Dose forms
AR057180A1 (es) Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion
RU2017134443A (ru) Способ лечения с применением традипитанта
TW200418517A (en) Liquid pharmaceutical formulations of palonosetron
CN103906756A (zh) 用于治疗疾病的方法
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
JP2015172060A5 (enExample)
Lei et al. A vaccine delivery system promotes strong immune responses against SARS‐CoV‐2 variants
JP2016512247A5 (enExample)
JP2016537364A5 (enExample)
Weiss Immunotherapy for HIV infection
JP2005508323A5 (enExample)
JP2015500836A5 (enExample)